Abstract: Objective: To compared the long-termed efficacy of 300 mg and 150 mg secukinumab  in the treatment of psoriatic arthritis (PsA). Methods: The studies about the efficacy of secukinumab 300 mg vs 150 mg in the treatment of psoriatic arthritis were searched in Pubmed, Cochrane Library, MEDLINE, EMBASE, CNKI, Wanfang and VIP. Meta-analysis was performed by RevMan 5.3 software. Results: Five papers were found, including 3 RCTs. There was no significant difference in response rate of 20%/50%/70% improvement of American College of Rheumatology (ACR 20/50/70), remission rate of enthesitis, and dactylitis between 300 mg and 150 mg secukinumab for the treatment of psoriatic arthritis at week 52. But compared with 150 mg secukinumab, 300 mg showed a greater improvement in response of PASI 75 and PASI 90 (P=0.002,0.01). Secukinumab 300 mg showed significantly higher ACR 20 and PASI 75 response rate than 150 mg in the TNFi-exposed group (P=0.006,0.04). There was no significant difference of these in the TNFi-naive group. Conclusion: There is no difference in improvement of joint damage between secukinumab 300 mg and 150 mg at week 52. However secukinumab 300 mg has an advantage in improvement of skin lesions. For TNFi-exposed patients with PsA, secukinumab 300 mg is more effective than 150 mg.

Key words: psoriatic arthritis, secukinumab, meta-analysis